Spyre Therapeutics Announces Positive Phase 1 Results for Anti-TL1A Antibody Programs and Phase 2 Clinical Development Plans

Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two investigational, extended half-life monoclonal antibodies tar...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Ct, Suite 450 Rockville, MD, 20850
info@pienomial.com
+91 9876543210
Copyright © 2025. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Spyre Therapeutics Announces Positive Phase 1 Results for Anti-TL1A Antibody Programs and Phase 2 Clinical Development Plans